Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

Two phase III clinical trials (CheckMate 141 and KEYNOTE 040) have independently demonstrated that overall survival (OS) in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients, who have failed platinum-based therapy, can be improved with anti-PD1 monotherapy. Treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pai, Sara I., Faivre, Sandrine, Licitra, Lisa, Machiels, Jean-Pascal, Vermorken, Jan B., Bruzzi, Paolo, Gruenwald, Viktor, Giglio, Raul E., Leemans, C. René, Seiwert, Tanguy Y., Soulieres, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446400/
https://www.ncbi.nlm.nih.gov/pubmed/30944020
http://dx.doi.org/10.1186/s40425-019-0578-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446400/
https://www.ncbi.nlm.nih.gov/pubmed/30944020
http://dx.doi.org/10.1186/s40425-019-0578-0

Ejemplares similares